$DNLI
Denali Therapeutics Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is DNLI down today? It is at $24.80 (-0.60%), and our scanner flagged it 53 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment DNLI spikes, and full due diligence on DNLI — key stats, earnings, dilution and insider activity. Free.
Get free $DNLI alerts the moment volume spikes
Our scanner flagged $DNLI 53 times in the last 30 days. Create a free account to track $DNLI, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $24.80
- Change today
- -0.60%
- Previous close
- $24.95
- 52-week range
- $12.58 – $27.30
- Market cap
- $3.99B
- Shares outstanding
- 159.8M Live vendor count
- Institutional own.
- 99.9%
- Total held
- 99.9%
- Tradeable float
- 160K 0% of shares · after 100% institutions
- Short interest
- 17.4M ▲ +9% vs prior · as of 2026-07-31
- Days to cover
- 12.1d
- Avg daily volume
- 1.8M
- Sector
- Health Care
- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- XNAS
- 5m
- 0.3x
- 15m
- 0.2x
- 1h
- 0.2x
- 1D
- 0.1x
Get free DNLI + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $DNLI down today?
Here is the latest on DNLI from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for DNLI today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystDenali Therapeutics Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filing4Insider trade (Form 4)Aug 14, 2026 · 6 days agoAnalyst data via Nasdaq. Not investment advice.
Insiders
Insiders buying8 buys, 2 sells last 3 months (11/5 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Watts Ryan J. Officer | Sold (automatic/other) | -32K 0.02% of company | sold 1.5% | 2.12M | n/a | Aug 12, 26 |
Schuth Alexander O. Officer | Sold (automatic/other) | -3K | sold 1.0% | 282K | $72K at $25.07 | Aug 11, 26 |
Baker Bros. Advisors Lp Director | Acquired (grant/award) | +13K | added 0.3% | 3.77M | n/a | Jun 3, 26 |
Cook Jennifer E. Director | Acquired (grant/award) | +6K | added 25% | 32K | n/a | Jun 3, 26 |
Van Hauwermeiren Timothy Director | Acquired (grant/award) | +6K | added 60% | 17K | n/a | Jun 3, 26 |
Thornberry Nancy Director | Acquired (grant/award) | +6K | added 26% | 31K | n/a | Jun 3, 26 |
Schenkein David P Director | Acquired (grant/award) | +6K | added 42% | 22K | n/a | Jun 3, 26 |
Krognes Steve E. Director | Acquired (grant/award) | +6K | added 20% | 38K | n/a | Jun 3, 26 |
Klein Peter S Director | Acquired (grant/award) | +6K | added 23% | 34K | n/a | Jun 3, 26 |
Flatley Jay T Director | Acquired (grant/award) | +6K | added 40% | 23K | n/a | Jun 3, 26 |
Schuth Alexander O. Officer | Sold (automatic/other) | -17K 0.01% of company | sold 5.7% | 283K | $284K at $16.50 | Jan 6, 26 |
Watts Ryan J. Officer | Sold (automatic/other) | -35K 0.02% of company | sold 11% | 297K | $581K at $16.50 | Jan 6, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Recent offeringAt-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing). If $DNLI runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- 11,428,571 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $189.3M in size
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$DNLI Sentiment
BearishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$DNLI Activity
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Stocks similar to DNLI
Comparable names in biological products, (no diagnostic substances), closest in size first.
DNLI stock FAQ
Why is $DNLI down today?
Here is the latest on DNLI from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for DNLI today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
What is the DNLI stock price today?
DNLI last traded at $24.80, down 0.60% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live DNLI alerts?
The DNLI Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged DNLI 53 times in the last 30 days.
What exchange is DNLI on?
DNLI (Denali Therapeutics Inc. Common Stock) trades on XNAS, with a market cap of about $3.99B in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Is DNLI good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge DNLI for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.